A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy

Sipola, Petri; Esko, Vanninen; Jantunen, Esa; Nousiainen, Tapio; Mikko, Kiviniemi; Hartikainen, Juha; Kuittinen, Taru

doi:10.1097/mnm.0b013e32834bfec4

Cited by 9 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many strategies have been developed to overcome the problem of DOX-induced cardiotoxicity. Clinical biomarkers monitoring (Cardinale et al., 2004 ; Dolci et al., 2008 ), strain echocardiography (Curigliano et al., 2012 ; Sawaya et al., 2011 ), heart rate (HR) variability assessment (Lončar-Turukalo et al., 2015 ), and radionuclide ventriculography (Sipola et al., 2012 ) have been used for the early diagnosis of subclinical forms of cardiotoxicity, in order to discontinue the treatment before irreversible damage occurs. Also, preventive treatments were attempted through the use of dexrazoxane that interferes with iron-mediated free radical generation and carvedilol, a vasodilating β blocker with antioxidant activity, but none seems to be effective enough (Mitry & Edwards, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats

et al. 2017

View full text Add to dashboard Cite

Conjugation of Doxorubicin (DOX) to N-(2-hydroxypropyl) methylacrylamide copolymer (HPMA) has significantly reduced the DOX-associated cardiotoxicity. However, the reports on the impact of HPMA–DOX conjugates on the cardiovascular system such as blood pressure (BP) and heart rate (HR) were in restrained animals using tail cuff and/or other methods that lacked the resolution and sensitivity. Herein, we employed radiotelemetric-spectral-echocardiography approach to further understand the in vivo cardiovascular hemodynamics and variability post administration of free DOX and HPMA–DOX. Rats implanted with radio-telemetry device were administered intravenously with DOX (5 mg/kg), HPMA–DOX (5 mg DOX equivalent/kg) and HPMA copolymer and subjected to continuous cardiovascular monitoring and echocardiography for 140 days. We found that DOX-treated rats had ruffled fur, reduced body weight (BW) and a low survival rate. Although BP and HR were normal, spectral analysis indicated that their BP and HR variabilities were reduced. All rats exhibited typical signs of cardiotoxicity at histopathology. In contrast, HPMA–DOX rats gained weight over time and survived. Although BP, HR and related variabilities were unaffected, the left ventricular end diastolic volume (EDV) of these rats, as well as of the HPMA copolymer-treated rats, was found increased at the end of observation period. Additionally, HPMA copolymer caused microscopic injury of the heart tissue. All of these suggest the necessity of caution when employing HPMA as carrier for prolonged drug delivery. The current study also indicates the potential of radiotelemetric-spectral-echocardiography approach for improved preclinical cardiovascular risk assessment of polymer–drug conjugate and other nano-sized-drug constructs.

show abstract

Section: Introductionmentioning

confidence: 99%

Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In both settings, cMRI was able to detect subclinical myocardial effects of anthracyclines. 16,17 In the present investigation, we proposed that cMRI would be able to detect early subclinical functional changes (LVEF and myocardial strain) while exploring structural changes (delayed gadolinium enhancement, GD-DE) in the anthracyclineexposed myocardium.…”

mentioning

confidence: 97%

Cardiac Magnetic Resonance Imaging for the Assessment of the Myocardium After Doxorubicin-based Chemotherapy

Lunning¹,

Kutty

Rome³

et al. 2015

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…The systematic bias between CMR and MUGA LVEFs has been variable in the literature [5, 25, 26]. The discrepancies are likely due to differences between institutions in imaging and analysis techniques, and software.…”

Section: Discussionmentioning

confidence: 99%

Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance

Huang

Nijjar

Misialek

et al. 2016

Journal of Cardiovascular Magnetic Resonance

View full text Add to dashboard Cite

BackgroundMultiple gated acquisition scanning (MUGA) is a common imaging modality for baseline and serial assessment of left ventricular ejection fraction (LVEF) for cardiotoxicity risk assessment prior to, surveillance during, and surveillance after administration of potentially cardiotoxic cancer treatment. The objective of this study was to compare the accuracy of left ventricular ejection fractions (LVEF) obtained by contemporary clinical multiple gated acquisition scans (MUGA) with reference LVEFs from cardiovascular magnetic resonance (CMR) in consecutive patients with cancer.MethodsIn a cross-sectional study, we compared MUGA clinical and CMR reference LVEFs in 75 patients with cancer who had both studies within 30 days. Misclassification was assessed using the two most common thresholds of LVEF used in cardiotoxicity clinical studies and practice: 50 and 55%.ResultsCompared to CMR reference LVEFs, MUGA clinical LVEFs were only lower by a mean of 1.5% (48.5% vs. 50.0%, p = 0.17). However, the limits of agreement between MUGA clinical and CMR reference LVEFs were wide at −19.4 to 16.5%. At LVEF thresholds of 50 and 55%, there was misclassification of 35 and 20% of cancer patients, respectively.ConclusionsMUGA clinical LVEFs are only modestly accurate when compared with CMR reference LVEFs. These data have significant implications on clinical research and patient care of a population with, or at risk for, cardiotoxicity.

show abstract

A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy

Cited by 9 publications

References 39 publications

Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats

Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats

Cardiac Magnetic Resonance Imaging for the Assessment of the Myocardium After Doxorubicin-based Chemotherapy

Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance

Contact Info

Product

Resources

About